Sage Therapeutics (SAGE)
(Real Time Quote from BATS)
$11.96 USD
+0.25 (2.14%)
Updated May 16, 2024 02:06 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 121 - 140 ( 157 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Bending to the Realities Facing Zulresso, Though Development Timelines for Pipeline Hold for Now; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Aiming to Accentuate Zuranolones Rapid Onset; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
With Map In Hand, They''re Running Down The Road Now
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Hurry Up and Wait for Clarity on Zulranolone; Lower Target to $78; Stay Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Waiting Is The Hardest Part; Uneventful 4Q19 As SAGE Waits For FDA Feedback
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Could Lower Exposure Explain SAGE-217/MOUNTAIN Miss?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
SAGE-217 Steps Into a Crevasse on the Way to the Summit; Lower Target, Reiterate Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Now, We''re Depressed - MOUNTAIN Fails To Meet Primary Endpoint
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Perspectives from KOL Dinner on Major Depressive Disorder
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Moving MOUNTAINs - Pivotal Readout Timing Narrowed to 4Q19
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Scaling the Big Mountains in CNS; Initiate at Neutral With $160 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Down But Not Out: Looking Ahead to 3Q19 Biotech Reporting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L